# A Phase 1b Study of Sevacizumab in Combination With Chemotherapy in Chinese Patients With Platinum-Resistant Recurrent Ovarian Cancer.

> **NCT03763123** · PHASE1 · UNKNOWN · sponsor: **Jiangsu Simcere Pharmaceutical Co., Ltd.** · enrollment: 48 (estimated)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Sevacizumab
- **DRUG:** Paclitaxel
- **DRUG:** Topotecan

## Key facts

- **NCT ID:** NCT03763123
- **Lead sponsor:** Jiangsu Simcere Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-04-24
- **Primary completion:** 2019-12-31
- **Final completion:** 2020-12-31
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2018-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03763123

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03763123, "A Phase 1b Study of Sevacizumab in Combination With Chemotherapy in Chinese Patients With Platinum-Resistant Recurrent Ovarian Cancer.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03763123. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*